In the present study, we continuously monitored NSE and proGRP levels during neoadjuvant chemoimmunotherapy in patients with LS-SCLC and found that ProGRP levels decreased significantly in both groups after neoadjuvant therapy, and this decrease was more obvious in group I (P=0.003). This evidence concerns the gene GRP and small cell lung carcinoma.